Trevi Therapeutics TRVI
NASDAQ TRVI
$17.19 +0.13 (+0.76%)
As of: Sep 4, 2026 · 3:12 PM EDT

Trevi Therapeutics (TRVI) Non Operating Interest Expenses (2018 - 2022)

Analysis

Trevi Therapeutics (TRVI) Non Operating Interest Expenses (2018 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Trevi Therapeutics 2.69 Bn 2.69 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 274,000.00
Sep 30, 2022 292,000.00
Jun 30, 2022 295,000.00
Mar 31, 2022 302,000.00
Dec 31, 2021 309,000.00
Sep 30, 2021 303,000.00
Jun 30, 2021 375,000.00
Mar 31, 2021 294,000.00
Dec 31, 2020 308,000.00
Sep 30, 2020 148,000.00
Jun 30, 2018 51,000.00
Mar 31, 2018 123,000.00